July 2008
Pharmaceutical Representative;Jul2008, Vol. 13 Issue 7, p10
The article offers updates related to the U.S. pharmaceutical industry. Critical Therapeutics Inc. and Cornerstone BioPharma Holdings Inc. sign a definitive agreement which will form Cornerstone Therapeutics. Astellas Pharma US Inc. and CoMentis Inc. agree to collaborate in developing and marketing beta-secretase inhibitors to treat Alzheimer's disease. Forest Laboratories Inc. and Daiichi Sankyo Co. Ltd. end their copromotion agreement for fixed-dose combination antihypertensive drug Azor.


Related Articles

  • TOP 20 PHARMA REPORT / TOP 10 BIOPHARMA REPORT.  // Contract Pharma;Jul/Aug2011, Vol. 13 Issue 6, p126 

    The article presents updates related to pharmaceutical and biopharmaceutical companies. The patent protection for the drug Plavix from the company Bristol-Meyers Squibb (BMS) will be extended for six months to May 2012. The drug tivozanib will be commercialized through the partnership between...

  • Critical Therapeutics Investors Balk Over Cornerstone Merger. Turner, Tiffany // BioWorld Today;5/5/2008, Vol. 19 Issue 87, p1 

    The article reports that Critical Therapeutics Inc. has disclosed merger plans with Cornerstone BioPharma Holdings Inc. in May 2008. Said merger aims to establish a specialty pharmaceutical company that will target on developing and commercializing drugs for respiratory indications. It is...

  • Japan Pharmas' Love for U.S. Biotechs Just Heating Up. Thiel, Karl // BioWorld Today;4/28/2008, Vol. 19 Issue 82, p1 

    The article focuses on strategic partnerships between Japanese pharmaceutical companies and the U.S. biotechnology sector. On April 25, 2008, Astellas announced it is partnering with South San Francisco, California-based CoMentis Inc. to develop a compound for Alzheimer's disease under a deal...

  • PRIVATE VIEW. Grillo, David // Medical Marketing & Media;Feb2009, Vol. 44 Issue 2, p62 

    The article highlights views on a number of medical advertisements published in the previous issues of the "MM&M" magazine in the U.S. The advertisements include the "No Fun for Anyone" tagline of MGI Pharma which was created by GSW Worldwide and "Cardiac Risk Factors" of Astellas Pharma US Inc....

  • Astellas, CoMentis in $760M Deal for Alzheimer's Treatment. Young, Donna // BioWorld Today;4/28/2008, Vol. 19 Issue 82, p1 

    The article reports on a partnership formed by Astellas Pharma Inc. with CoMentis to develop a compound for Alzheimer's disease. Under the deal, Astellas will pay an up-front fee of $80 million to CoMentis in exchange for the worldwide commercialization rights to CTS-21166, an oral...

  • Astellas, CoMentis in $760M Deal.  // Bioworld Week;5/5/2008, Vol. 16 Issue 18, p2 

    The article reports on the partnership between Japanese drugmaker Astellas Pharma Inc. and Comentis Inc. to develop a compound for Alzheimer's disease in a deal expected to be worth $760 million. Under the agreement, Astellas will pay an up-front fee of $80 million to South San Francisco-based...

  • Annual update on new approvals, indications.  // Cardiology Today;Jan2008, Vol. 11 Issue 1, p1 

    The article introduces a series of articles about drugs that received approvals and indications from the U.S. Food and Drug Administration in 2007. They include the approval of Nebivolol from Forest Laboratories and a beta-blocker for hypertension and recommendations for the approval of...

  • Astellas Transfers Three European Plants to Temmler Group. Van Arnum, Patricia // Pharmaceutical Technology;Feb2007, Vol. 31 Issue 2, p18 

    The article reports on the move of Astellas Pharma Inc. to turnover its European plants to the Temmler Group, a pharmaceutical company and contract manufacturer. This is part of Astellas' plan to reduce the number of its production sites. Astellas will receive a special charge of $39 million as...

  • Biotech Collaborations Between Pharmaceutical & Miscellaneous Companies: June 1 - August 13, 2013.  // BioWorld Insight;08/19/2013, Vol. 21 Issue 34, p21 

    A table is presented which lists biotechnology collaborations between several pharmaceutical and miscellaneous companies across the globe from June 1 to August 13, 2013 including Astellas Pharma US Inc. with Tecnofarma International Ltd., Meda AB and Cipla Ltd., and Medivir AB with Unimedic AB.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics